SRF Limited Q2 & H1 FY26 Concall Decoded: Chemicals on Fire, CFO on Farewell Tour 🔥
1. Opening Hook
Markets may be melting, but SRF’s chemicals seem to be boiling over — and just as things get spicy, CFO Rahul Jain decides to hang up his lab coat. Timing, anyone? Amid global slowdown and China dumping polymers like clearance sale flyers, SRF somehow cooked up a 93% PAT surge. Divine intervention or disciplined execution? As the Bhagavad Gita says: “Karmanye vadhikaraste ma phaleshu kadachana” — do your duty, don’t chase the results. Well, SRF did its karma, and the results chased them. Keep reading — it gets fluoro-nominally interesting. 😏
2. At a Glance
Revenue up 6% – CFO insists it’s “momentum,” not “mutant molecules.”
EBIT up 56% – Looks like the Chemistry lab finally went commercial.
PAT up 93% – From flask to cash flask.
Margins at 18% – Cost gremlins exorcised, mostly.
Chemicals biz +23% – SRF now runs on refrigerants and caffeine.
Capex bumped to ₹2,300 cr – Because why not expand when the world panics.
Stock steady – Investors are waiting to see if post-Rahul chemistry still clicks.
3. Management’s Key Commentary
“Our Chemicals business grew 23% driven by higher refrigerant volumes.” (Translation: Air conditioners are the new gold mines, and we’re mining hard.)
“PAT expanded by 93% YoY.” (Or as traders say, “That escalated quickly.” 😳)
“We entered a strategic partnership with Chemours for fluoropolymers.” (Read: SRF just got invited to the global chemistry cool kids’ table.)
“Odisha land purchase of ₹282 crore for future chemical facilities.” (Because Gujarat’s full, and Odisha’s the next lab on the map.)
“R&D now has 450 professionals, 501 process patents filed.” (So basically, a small nation of chemists weaponized with pipettes and patents.)
“Performance Films flat but higher EBIT.” (A polite way of saying: prices didn’t move, but we squeezed harder.)
“Finance costs reduced, but forex hit P&L.” (Rupee slipped on the lab floor — still, CFO didn’t flinch.)
“I’ll step down as CFO in December.” (Cue: “You either die a hero or retire before the next chemical cycle.” 🧪)
4. Numbers Decoded
Metric
Q2 FY26
YoY Change
One-Line Analysis
Revenue
₹3,640 Cr
+6%
Growth still cooking despite global chill.
EBIT
₹650 Cr
+56%
Margin chemistry finally stabilized.
PAT
₹388 Cr
+93%
CFO’s farewell gift to shareholders.
Chemicals Biz Revenue
₹1,667 Cr
+23%
Fluorochemicals on fire; Specialty solid.
Performance Films Revenue
₹1,408 Cr
Flat
Same movie, better popcorn sales.
Technical Textiles Revenue
₹474 Cr
-?
Imports from China hit hard.
Capex Guidance FY26
₹2,300 Cr
N/A
Expansion party continues, land included.
Margin magic met forex tragedy — but SRF still emerged as India’s chemical Iron Man.
5. Analyst Questions
On Pharma Intermediates: “Are we ramping?” – “Not yet, but dreams
